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Our goal has been to evaluate the importance that the incorporation of Bcl2 in the ER/PGR/
Her2/Ki67 bio-profile can have as predictor of the Oncotype Dx categories.
Material and methods
156 consecutive cases of HR+/Her2- pN0/1 primary breast carcinoma were sent to the
Oncotype Dx test. Immunohistochemical determination of Bcl2/ER/PGR/Ki67/Her2
expression was evaluated for each case. After the selection of the appropriate cut-off val-
ues for PGR and Ki67, explorative as well as confirmative statistical analyses were per-
formed to build and validate predictive risk-of-recurrence immunohistochemical only bio-
profiles.
Results
The predictive capacity of these immunohistochemical profiles was compared with both tra-
ditional and TAILORx Oncotype Dx risk class classification. This comparison showed that
immunohistochemical bio-profiles select those cases not associated with high risk-of-recur-
rence of disease (luminal-A/B and luminal A/B Bcl2) and those that are instead at high risk
and therefore worthy of chemotherapy (luminal-B ki67 and luminal-B Bcl2/Ki67), strongly
suggesting to only submit PGR-positive/Bcl2-Ki67 altered cases to Oncotype Dx, thus
reducing the number of cases to be tested.
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Conclusions
Our results indicate that the addition of Bcl2 to an immunohistochemical bio-profile definitely
improves its predictive capacity to correctly select which cases to send to the Oncotype Dx
test. We have also suggested that institutions with a significant number of breast carcino-
mas sent to the Oncotype Dx test can use these latter to derive their own PGR and Ki67 cut-
off values, overcoming the drawbacks of sharing common inter-laboratory values. Validation
of these bio-profiles as predictors of the Oncotype Dx categories is ongoing in a prospective
series of new cases.
Introduction
The most recent TNM AJCC classification (8th edition) [1] has defined breast cancer as a
group of diseases with different molecular characteristics, and promoted the addition of spe-
cific biomarkers to guide personalized systemic therapies. In the light of this perspective, the
determination of ER, PGR and Her2 expression using immunohistochemistry (IHC) or multi-
gene panels is today part of TNM AJCC prognostic staging. Risk assessment is crucial to plan
correct therapies in breast cancer, and in the light of this need, it is important to properly dis-
tinguish those Hormonal Receptor (HR)-positive/Her2-negative cases that required chemo-
therapy. This risk assessment has gained significant improvement by the introduction of
Oncotype Dx molecular assay (Genomic Health, Redwood City, CA, USA). This molecular
21-gene assay quantifies the risk of distant recurrence at 10 years from diagnosis (Recurrence
Score—RS) giving a retrospective (NSABP B14 and B-20) and prospective (TAILORx) vali-
dated indication of the potential benefit of chemotherapy for those HR-positive/Her2-negative
N0 cases [2,3]. In addition, the Oncotype Dx report contains qRT-PCR results for ER, PGR
and Her2, all of which are further classified using specific cut-off values.
Similarly, in routine practice, the integration of ER, PGR and Her2 values determined with
IHC and quantified according to specific cut-off values support luminal classification. The rec-
ommendations of the ASCO/CAP guideline for IHC hormone testing stated that 1% of immu-
nostained cells are the correct cut-off value to distinguish between positive and negative ER
and/or PGR cases [4]. However, as far as the evaluation of PGR is concerned, this statement is
not completely shared by oncologists; indeed a 20% cut-off was proposed at the St. Gallen con-
sensus meeting in 2013, and a 10% cut-off is considered valid by several authors [5–8]. With
regard to Her2 IHC classification, the ASCO/CAP recommendations allow us to distinguish
negative (score 0/1+) from equivocal (score 2+) or positive (score 3+) cases; equivocal scores
will then be changed to negative or positive using in situ hybridization. Further, Ki67 IHC
could also be of help to distinguish luminal-A from luminal-B cases [9]. The relevance of Ki67
is supported by its proven relationship with the Oncotype Dx risk-of-recurrence assessment
[10–13]. However, its prognostic/predictive role is hindered by at least two important draw-
backs: reproducibility and selection of the cut-off value [9,14–17].
In our institution, Bcl2 was added to the above-mentioned IHC prognostic markers to bet-
ter distinguish between luminal A/B subtypes. Bcl2 presence was positively associated with
favorable prognostic features in breast cancer, emerging as an independent predictor for either
DFS or OS [18–21]. It is noteworthy that Bcl2 is also part of the 21-gene Oncotype Dx
signature.
Being part of the PONDx Survey, we sent to the Oncotype Dx test all the early HR-positive/
Her2-negative, pT1/2, pN0/1 luminal cases diagnosed in 2017. We then decided to compare
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our established IHC bio-profile with the Oncotype Dx Recurrence Score. The purpose of the
present study is to evaluate whether a proper IHC profile could be used as a reliable screening
tool to predict Oncotype Dx risk categories, helping in identifying those patients who really
need this test for treatment decision in early breast cancer.
Materials and methods
The study was approved by the CE-AVEC (Comitato Etico—Area Vasta Emilia Centro) regis-
ter n˚ 668/2018/Oss/AOUBo. All patients signed an informed consent permitting the use of
the data necessary for the study.
Patients characteristics
In our institution, 156 consecutively patients diagnosed with HR-positive/Her2-negative,
pN0/1, pT1/2 early breast carcinoma were referred to Oncotype Dx testing by the Breast Can-
cer Multidisciplinary Team from 12th December 2016 to 22th December 2017. The immuno-
histochemical bio-profile was integrated into the diagnosis. Patients mean age was 61.8 years
(range 35–93). The majority of cases presented a diagnosis of invasive carcinoma No Special
Type (126 cases– 80.8%), and pT1c (47.7%) pN0 (70.1%) pathological stage. Patients character-
istics were reported in Table 1. The tumors were histologically classified according to WHO
2012 criteria. Tumor staging (pTN) was defined following TNM AJCC classification [1].
Tumor grading was performed according to Elston & Ellis criteria. Axillary lymph node status
was evaluated following the sentinel node approach.
Immunohistochemistry
Following surgical resection, tissues were sent to the Surgical Unit for histopathologic exami-
nation by a dedicated pathologist. Formalin-fixed (12-72h), paraffin-embedded tumor sections
were obtained and processed in a Benchmark Ultra immunostainer (Ventana Medical Sys-
tems, USA) for ER, PGR, Bcl2, Ki67, and Her2 determination (S1 Table).
Visualization of the immunological reaction was obtained with OptiView DAB Detection
kit for ER, PGR, Bcl2 and ki67 staining or with UltraView DAB Detection kit for Her2 stain-
ing; slides were counterstained with haematoxylin and bluing reagents.
The percentage of ER, PGR, and Ki67 stained cells was quantified using image cytometry
with the IMAGE Pro Plus 5.1 software (Media Cybernetics Inc., USA). For ER and PGR deter-
mination the entire section was quickly examined at 10x and then at least twenty-five 200x rep-
resentative fields scattered in the section were selected, captured, and examined with the
software. Ki67 was evaluated on the entire invasive front, counting at least 5.000 cells per case.
A labelling index (%Li) was obtained for each of these parameters and expressed as percentage
of positive cells on total neoplastic counted cells. Bcl2 immunohistochemical expression was
Table 1. Patients and tumor characteristics.
Age (years) Mean ± S.D. 61.8±12.9 Range 35–93 Cases� 50 years 38 Cases > 50 years 118
Histologic subtype IC-NST 126 (80.8%) ILC 25 (16.0%) ICDL 5 (3.2%)
Tumor Grade G1 67 (43.2%) G2 70 (45.2%) G3 18 (11.6)
Tumor size (mm) Mean ± S.D. 15.6±8.1 Median 13.5
pTN stage T1a 3 (1.9%) T1b 52 (33.5%) T1c 74 (47.7%) T2 26 (16.9%)
N0 108 (70.1%) Nmic 14 (9.1%) N1 32 (20.8%)
IC-NST = Invasive Carcinoma No Special Type; ILC = Invasive Lobular Carcinoma; ICDL = Invasive Carcinoma with mixed Ductal and Lobular features
https://doi.org/10.1371/journal.pone.0217937.t001
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quantified modifying a previously validated semiquantitative method based on its distribution
and intensity in neoplastic cells [18]. Cases were classified as: Bcl2 High = presence of a moder-
ate to intense homogeneous staining in all cancer cells; Bcl2 Low = all the remaining cases.
Oncotype Dx
Sections for Oncotype Dx testing were obtained from the same formalin-fixed, paraffin-
embedded tissue block sectioned for immunohistochemical bio-profile. Cases were referred to
Oncotype Dx assay after a multidisciplinary meeting evaluation, considering clinical, patho-
logical, and bio-pathological conventional prognostic parameters. The RS results were classi-
fied into Low- (L), Intermediate-(I), and High-risk (H) group according to both traditional
(RS<18; RS 18–30; RS>30) and the recently proposed TAILORx trial (RS<11; RS 11–25;
RS>25) cut-off values [3]. Oncotype (-Dx) ER, PGR, and Her2 qRT-PCR values and their rela-
tive classification were also recorded.
Statistical analysis
The aim of statistical analysis was to verify the extent to which a panel of immunohistochemi-
cal markers correlates with the classes of risk obtained with Oncotype DX. Statistical analysis
includes Pearson’s Correlation, Concordance and Multinomial logistic regression. Principal
component analysis (PCA) for continuous variables and multiple correspondence analysis
(MCA) for categorical variables were included for exploratory purposes. PCA analytical tech-
niques are useful to explore association among variables while MCA explore association
among different categories [22]. Multinomial Logistic regression using Jackknife resampling
procedure [23] was conducted with Stata software v 11.0 (Statcorp, USA).
Results
Oncotype Dx cases classification
The Oncotype Dx RS values of our 156 cases were classified according to both traditional as
well as TAILORx cut-off values. Using the traditional classification, 106 (67.9%) cases were at
Low risk, 42 (26.9%) cases were at Intermediate risk, and 8 (5.2%) cases were at High risk.
Using the recently validated TAILORx cut-off values cases were classified as: 40 (25.6%) at
Low risk, 102 (65.4%) at Intermediate risk, and 14 (9.0%) at High risk, showing the expected
slippage of many Low-risk cases towards the Intermediate risk due to the reduction of cut-off
values introduced by the TAILORx trial.
Correlations between immunohistochemical markers and Oncotype Dx
values
ER, PGR, and Her2 evaluation. - All cases sent to Oncotype evaluation were confirmed
ER-positive and Her2-negative by qRT-PCR assay. Considering ER%Li distribution, 139
(89.1%) cases showed all neoplastic cells positive for estrogen receptor expression with their
corresponding ER-Dx values ranging from 7.9 to 12.5 units. These values encompassed the
great majority of qRT-PCR positive range (6.5 -�12.5 units). No significant association was
found between ER%Li and ER-Dx due to the high preponderance of 100% ER%Li (Fig 1A).
Instead, a significant association was found between PGR%Li and PGR-Dx determination (Fig
1B). Of the 156 cases tested for Her2 IHC, 91 (58.3%) were Score 0, 46 (29.5%) were Score 1+,
and 19 (12.2%) were Score 2+/ISH not amplified cases. Oncotype Her2 (Her2 Dx) determina-
tion classified 151 (96.8%) cases as Negative and 5 (3.2%) cases as Equivocal. Kruskal-Wallis
test showed a relationship between Her2 IHC and Her2-Dx qRT-PCR values (S2 Table) clearly
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depicted using a Box Plot graphic display (Fig 2). In order to make the assessment of Her2
comparable between the two methodologies, we refined the Her2-IHC classification, consider-
ing Score 0/1+ or Score 2+/ISH not amplified as Her2 Negative, and Score 2+/ISH equivocal
as Her2-IHC equivocal. The comparison between Her2-IHC thus reclassified (3 equivocal)
and Her2-Dx (5 equivocal) shows 6 discordant cases as follows: 4 Her2-Dx Equivocal classified
as Her2-IHC negative, 2 IHC Equivocal classified as Her2-Dx negative. This is in line with the
observation reported by Dabbs et al. [24] on the different classification of equivocal cases
between Her2 IHC/FISH and Oncotype Dx qRT-PCR. No significant association was found
between reclassified Her2 IHC cases and RS (Mann-Whitney test Z = -1.007; p = 0.592). On
the contrary a significant association was found when considering Her2 Dx classes (Mann-
Whitney test Z = -2.048; p = 0.002).
A principal component analysis (PCA) conducted on ER, PGR and Her2 evaluated for
either Oncotype or IHC tests confirms the strong inverse correlation between Oncotype RS
and PGR levels already reported in the literature [25,26]. ER is faibly associated with RS in the
IHC analysis but not in the Oncotype counterpart. Instead in both analyses was associated to
Her2 as it appeared in the second Eigenvector (S1 Fig).
Fig 1. Bivariate Scatter Plots of ER, PGR, and Ki67 IHC versus Oncotype Dx. Bivariate Scatter Plots of (A) Estrogen
Receptor IHC versus ER Oncotype Dx; (B) Progesterone Receptor IHC versus PGR Oncotype Dx; (C) Ki67 IHC
versus Oncotype Dx Recurrence Score.
https://doi.org/10.1371/journal.pone.0217937.g001
Fig 2. Box Plot analysis of Her2 IHC versus Her2 Oncotype Dx.
https://doi.org/10.1371/journal.pone.0217937.g002
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Overall, considering only these three markers, the presence of ER in our series simply asso-
ciated with the "luminal" pattern, while the extent of PGR presence was mainly associated with
risk-of-recurrence. PCA analysis confirmed Her2 IHC not associated to RS (S1 Fig). This
observation, combined with the presence of a few equivocal Her2 IHC cases, their different
classification compared to Her2 Dx, and especially the lack of any significant association
between Negative/Equivocal cases and RS, led us to exclude Her2 in our IHC bio-profiles.
Ki67 and Bcl2 evaluation. - Information regarding the other two IHC markers (Ki67 and
Bcl2) are not directly reported in the Oncotype schedule. For these markers RS is the only
informative parameter from which to obtain any predictive value. We have therefore evaluated
this aspect by extrapolating it directly from the results of the Oncotype Dx test on our dataset.
Ki67%Li was moderately associated to RS (Fig 1C); Bcl2 IHC showed 125 (80.1%) High cases
and 31 (19.9%) Low cases and was inversely related to RS, (S2 Table), with RS mean values of
14.2 for Bcl2-High cases and 21.7 for Bcl2-Low cases.
Multinomial ordinal logistic regression analysis confirmed Bcl2, PGR, and Ki67 as indepen-
dent risk factors significantly correlated with traditional as well as TAILORx risk class classifi-
cation (Table 2).
Tailored predictive cut-off values for Ki67 and PGR IHC bio-markers
Since PGR and to a less extent Ki67 emerged as informative parameters for this classification,
we had to choose an appropriate cut-off value allowing us to correctly separate PGR negative
versus positive cases and the high Ki67 cases from the low ones. Cut-off values derived from
the literature [9,17,27] were all obtained in a prognostic context and do not display the needed
predictive value. Consequently, we defined specific cut-off values for PGR and Ki67 according
to the RS of the Oncotype Dx test. Comparing PGR-Dx risk classification with PGR%Li values,
the cut-off that best reflects the distribution of risk classes was found to be 4%. Using this cut-
off value, the comparison between the PGR IHC vs Dx classification showed a concordance in
147 (94.2%) cases (S2 Table). The distribution of the Oncotype Dx risk class for PGR IHC vs
Dx showed 153 (98.1%) concordant cases for traditional classification, and 155 (99.4%) con-
cordant cases for TAILORx classification (Table 3). In summary, the 4% PGR IHC cut-off
value appears to be as informative as its Oncotype counterpart, especially for TAILORx classi-
fication. For Ki67%Li, the evaluation by ROC Plot Analysis of which could be the best cut-off
value to distinguish high risk from intermediate/low risk cases (Fig 3) suggested 25% as the
most informative value. Applying this value to our cases, all Oncotype Dx High risk patients
Table 2. Multiple multinomial logistic regression analysis of Oncotype risk class classification vs PGR, Ki67, and
Bcl2.
Oncotype Traditional Risk-class High/Intermediate/Low Effect Likelihood Ratio Tests: Whole model test:
ChiSquare = 91.749, p < 0.0001
Source Units DF L-R ChiSquare P > ChiSq
Bcl2 High/Low 1 11.611 0.0007
PGR %LI 1 34.766 < 0.0001
Ki67 %LI 1 39.298 < 0.0001
Oncotype TAILORx Risk-class High/Intermediate/Low Effect Likelihood Ratio Tests: Whole model test:
ChiSquare = 78.479, p < 0.0001
Source Units DF L-R ChiSquare P > ChiSq
Bcl2 High/Low 1 8.339 0.0039
PGR %LI 1 29.266 < 0.0001
Ki67 %LI 1 31.159 < 0.0001
https://doi.org/10.1371/journal.pone.0217937.t002
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had values of Ki67>25%Li (Ki67-High), while all those classified at Low/Intermediate risk had
values of %Li�25% (Ki67-Low), both for traditional and for TAILORx Oncotype (S3 Table).
Building and validating the predictive immunohistochemical profile
Taking in account these results, we tried to define which could be the main IHC profiles that
can best predict the correct classification of early breast carcinoma according to the two main
Oncotype Dx risk class categories: Oncotype Low/Intermediate risk of distant recurrence;
Oncotype High risk of distant recurrence. For this purpose, we used an explorative analysis
(correspondence analysis) carried out by combining the classification of bio-pathological
parameters that we proved to be significantly associated with the Recurrence Score, (Bcl2 Low/
High, PGR Neg/Pos, Ki67 Low/High), and the risk classes as defined by traditional and TAI-
LORx Oncotype.
From this exploratory analysis combined Ki67-High/Bcl2-Low and Ki67-Low/Bcl2-High
expression closely associated respectively with the high (H) and low (L) risk classes (S2 Fig).
The expression of PGR presents a different behavior. PGR positive results are clearly associated
to a Low/Intermediate risk, while a PGR negative result associated to Intermediate than High
risk tumors (S2 Fig). Therefore, it seems that PGR is more indicative of the hormonal biologi-
cal background of the tumor, while the other two parameters characterize more decisively the
High and Low risk classes.
Table 3. PGR IHC (4%Li cut-off value) and PGR Dx (5.5 cut-off value) RS risk class distribution.
Low Risk n˚ Cases PGR Dx Neg PGR Dx Pos PGR IHC Neg PGR IHC Pos Δ
Traditional 106 5 101 6 100 1
TAILORx 40 0 40 0 40 0
Intermediate Risk PGR Dx Neg PGR Dx Pos PGR IHC Neg PGR IHC Pos Δ
Traditional 42 11 31 9 33 2
TAILORx 102 14 88 13 89 1
High Risk PGR Dx Neg PGR Dx Pos PGR IHC Neg PGR IHC Pos Δ
Traditional 8 5 3 5 3 0
TAILORx 14 7 7 7 7 0
Δ = n˚ of discordant cases
https://doi.org/10.1371/journal.pone.0217937.t003
Fig 3. Binomial ROC curve for the identification of the most informative cut-off value for Ki67%Li. TPF (True
Positive Fraction); FPF (False Positive Fraction).
https://doi.org/10.1371/journal.pone.0217937.g003
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All this information suggested us to consider at least two different biological landscapes, a
PGR-Neg and a PGR-Pos ones that we could define as luminal-A (Lum-A) and luminal-B
(Lum-B), in which to put Bcl2 and Ki67 Low/High classification. As a result, for each luminal
group we obtained 4 subgroups: Lum-A/B (no Bcl2/Ki67 alterations); Lum-A/B Bcl2
(Bcl2-Low); Lum-A/B Ki67 (Ki67-High); Lum-A/B Bcl2/Ki67 (Bcl2-Low/Ki67-High).
Both Lum-A and -B groups showed a growth of mean RS values from no alteration to the
combined alteration of Bcl2/Ki67, with Lum-B subtypes having a higher mean RS value respec-
tive to their Lum-A counterpart, except for Bcl2 subtypes (Table 4).
If we consider the distribution of Oncotype Dx Risk groups according to our immunohisto-
chemical subgroups, we observed no High-risk cases present in the subgroups Lum-A/B, or in
those with only Bcl2 alteration. Otherwise, considering Lum-A group, High-risk cases were
predominantly located in the Lum-A Bcl2/Ki67 subgroup, while in Lum-B group High-risk
cases were clustered in Lum-B Ki67 and Lum-B Bcl2/Ki67 subgroups (Table 4). Restriction of
the analysis only to pN0 cases confirmed the above reported results, showing for Lum-A Bcl/
Ki67 subgroup an even higher incidence of High-risk cases, especially using TAILORx classifi-
cation (S4 Table).
By adapting the classification of IHC subgroups to that of Oncotype Dx, three main predic-
tive classes are obtained: Low risk IHC class (Lum-A/B and Lum-A/B Bcl2); High risk IHC
class (Lum-B Ki67 and Lum-B Bcl2/Ki67); Intermediate risk IHC class (Lum-A Ki67 and
Lum-A Bcl2/Ki67). Overall accuracy is low (75% - 117/156 Oncotype Traditional; 44.2% - 69/
156 TAILORx) due to the different classification of Low and Intermediate risk cases between
IHC and Dx, but the predictive values are in line with our objective. Indeed, the predictive
value of the Low risk IHC class for the presence of Oncotype High risk cases is 0% (0/114
cases) for both Traditional as well as TAILORx classification, whereas for the High risk IHC
class it is 71.4% (5/7 cases) for Traditional and 100% (7/7 cases) for TAILORx (Table 4). The
predictive value of the intermediate risk class IHC is low—8.6% (3/35 cases) Traditional,
20.0% (7/35 cases) TAILORx, thus confirming that the latter IHC subgroups include those
cases that need to be sent to the Oncotype test for a correct classification of their risk.
Since we are currently unable to provide confirmation of data on a new set of patients, we
cross-validated the results of the multinomial logistic regression by performing Jackknife
resampling procedure that has confirmed the results. The yield of the three covariates by Jack-
knife cross-validation are reported in the S5 Table.
Table 4. Oncotype Dx Recurrence Score (RS) and risk groups distribution among IHC subgroups.
Luminal IHC subgroup N˚ cases RS (mean ± S.D.) Oncotype risk groups distribution
Traditional TAILORx
L I H L I H
Lum-A 90 11.5 ± 4.7 82 8 0 36 54 0
Lum-A Bcl2 11 16.7 ± 6.6 5 6 0 1 10 0
Lum-A Ki67 20 18.2 ± 7.4 10 9 1 3 15 2
Lum-A Bcl2/Ki67 15 22.5 ± 6.4 3 10 2 0 10 5
Lum-B 11 18.9 ± 3.9 5 6 0 0 11 0
Lum-B Bcl2 2 17.5 ± 3.5 1 1 0 0 2 0
Lum-B Ki67 4 41.5 ± 9.5 0 1 3 0 0 4
Lum-B Bcl2/Ki67
l
3 39.0 + 7.9 0 1 2 0 0 3
Lum-A (luminal-A) = PGR < 4%, Lum-B (luminal-B) = PGR� 4%; S.D. = Standard Deviation; L = Low risk;
I = Intermediate risk; H = High risk
https://doi.org/10.1371/journal.pone.0217937.t004
Bcl2 and Oncotype Dx pre-selection in breast carcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0217937 June 3, 2019 8 / 13
Discussion
Many studies already exist in literature disputing about a simpler predictive value attributed to
immunohistochemical bio-profile as opposed to the most expensive but validated Oncotype
Dx assay. Of note, at least PGR and proliferation emerge as main players from these studies
[13,25,26], in accordance to the predominant role in the RS algorithm presented by Paik et al.
[2]. PGR IHC determination was already demonstrated equal to its Oncotype counterpart,
especially when H-score method was used [28]. Moreover, when its expression is classified
into Negative vs Positive cases an overall concordance between PGR IHC and Dx ranging
from 85.8% to 91.3% was reported [28–32], and an inverse relation with RS is also convinc-
ingly demonstrated [28–31,33]. Our results are in line with these previously reported observa-
tions. Linear regression analysis showed a good relationship between PGR IHC and its
molecular counterpart (R2 = 0.731). Principal component analysis on Oncotype or IHC ER,
PGR, Her2 and RS confirmed the strong inverse relation between RS and PGR [25,26], and
multinomial logistic regression analysis demonstrated an independent association to RS pre-
dictive risk-of-recurrence value for PGR IHC. Estrogen Receptor seems to play a minor role in
this situation also if a relationship between ER IHC and its Oncotype counterpart was reported
[28]. In our cases, the comparison between IHC and Oncotype ER and PGR values showed a
relationship for PGR, but not for ER. Moreover, principal component analysis showing the
absence of correlation between ER IHC and RS, suggests that the predictive role of ER IHC is
irrelevant here, contributing this latter only to define cases as “luminal”.
Ki67 immunohistochemical determination was already shown to directly correlate with RS,
despite the difficulty of comparing the reported results due to different scoring methods and
cut-off values [11–13,34]. In our series we found a moderate relationship between Ki67 IHC
and RS (R2 = 0.322). Despite this, we demonstrated a strong and independent relationship
between Ki67 and RS (Table 2), both for traditional and TAILORx risk class classification.
As regards the determination of Her2, the results obtained are clearly contradictory. In fact,
although there is a significant association between Her2 IHC and the respective qRT-PCR val-
ues (Fig 2; S2 Table), the multivariate PCA analysis does not show any significant association
with RS (S1 Fig). The same lack of association is detectable by considering the classification of
Her2 in Negative vs. Equivocal, unlike its counterpart Her2 Dx, which is directly related to RS
(Mann-Whitney test Z = -2.048; p = 0.002). That there may be a discrepancy between Her2
IHC and Dx is already reported by Dabbs et al. [24], particularly in the classification of Equivo-
cal cases. It should also be noted that the poor representativeness of the latter class in our series
(3 cases of IHC, 5 cases of Oncotype), may have accentuated this discrepancy. In the light of
these considerations we have excluded this parameter from the evaluation of the IHC bio-pro-
file as predictor of the risk classes Oncotype Dx.
In clinical practice, in order to predict the need of chemotherapy in luminal cases, ER,
PGR, and Ki67 are not separately considered, but combined together in the attempt to distin-
guish luminal-A from -B bio-profiles. The most convincing evidence that combination, rather
than single consideration, may be the right approach was the “IHC4” score proposed by
Cuzick et al, demonstrating on TransATAC trial dataset the ability to predict outcome better
than Oncotype Dx [10]. According to ASCO/CAP and St.Gallen recommendations, luminal-B
bio-profile encompasses all cases Her2-negative with a low ER and/or PGR expression. What
we have to intend with the term “low” is already debatable, because at least three different cut-
off values (�1%-20%-10%) were proposed [5–8]. Ki67 cut-off values suffer the same drawback,
ranging from 14% to 20–30% depending on what recommendation we take in account [9,14–
17]. Whatever the selected value is, papers dealing with IHC vs Oncotype Dx risk-of-
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recurrence predictive value all considered an “a priori” (prognostic) cut-off value, instead of
defining one clipped on Recurrence Score results.
To integrate PGR and Ki67 into a simple predictive bio-profile we have defined specific cut-
off values, tailored on Oncotype RS. For PGR IHC it means that we need a value that mirrors
the same risk class distribution of its Oncotype counterpart. We found 4% as the cut-off value
corresponding to this necessity. Using this value, concordance between PGR IHC and Dx Nega-
tive vs Positive cases was 94.2%, a very good result regarding to the literature [28–32]. Most
important, comparing PGR IHC or Dx classification of cases using Oncotype Risk class distri-
bution, 153/156 (98.1%) cases showed the same attribution using traditional risk class, and only
1 case was discordant following the recently proposed TAILORx cut-off values (Table 3). In
brief, PGR IHC 4% cut-off value seems to be as informative as its Oncotype counterpart.
For Ki67 evaluation, we confirmed its independent relationship with Oncotype RS, as dem-
onstrated by principal component and logistic regression analysis, and as for PGR, to integrate
its predictive value in the IHC bio-profile we select a proper cut-off value. ROC curve analysis
showed 25%Li as most appropriate to divide High risk cases from the Intermediate/Low ones
(Fig 3).
Very few papers reported Bcl2 as a possible partner of these bio-profiles, despite it was
clearly demonstrated as a significant prognostic marker in breast cancer [18–21], and is part of
the hormonal-related Oncotype Dx signature. Bcl2 is added to our analysis taking part of our
IHC bio-profile until 1995. Bcl2-IHC determination showed a significant inverse relation with
RS (S2 Table), and multinomial logistic regression analysis confirmed its independent associa-
tion with Oncotype traditional and TAILORx risk class classification.
At the best of our knowledge this is the first time that Bcl2 is reported as an independent
significant predictor of Oncotype risk-of-recurrence score.
Based on these findings, we have built specific IHC bio-profiles tailored on Oncotype Risk-
of-recurrence classification. Correspondence analysis suggested us a “landscape” role for
PGR-IHC, identifying two large groups, PGR-Positive (Lum-A) and PGR-Negative (Lum-B),
on which to fall the other indicators (Bcl2, Ki67). Therefore, each group was split into four sub-
groups: no alteration (Lum-A/B); Low Bcl2 (Lum-A/B Bcl); High Ki67 (Lum-A/B Ki67); com-
bined Bcl2 Low and High Ki67 (Lum-A/B Bcl/Ki67). Considering the distribution of High-
risk cases defined by Oncotype traditional as well as TAILORx RS cut-off values, only luminal
Ki67-High or combined Bcl2-Low/Ki67-High subgroups shared their presence, with the last
ones having the higher incidence of High-risk cases, especially when TAILORx classification
was applied and irrespective of the pN status (Table 4, S4 Table).
It is necessary to note that there are some limitations to our study. The number of cases
considered is rather small, and may be that the irrelevance of ER and Her2 IHC here found is
related to this drawback. Moreover, the suggestions we have reported are conditioned by an
observer-dependent evaluation of the IHC parameters, especially for ER and PGR (no H-
score), also if for PGR IHC this seems not so relevant.
Finally, and most importantly, we know that for the validation of this IHC predictor it is
necessary to confirm these results on a further dataset of patients. The collection of a sufficient
number of cases is ongoing but it will require quite a long time. However, Jackknife resampling
procedure cross-validation of our results may strongly suggest in our opinion that IHC profiles
built using the proposed methodology may be a useful predictor of Oncotype Dx categories.
Conclusions
In conclusion, we have shown that for the best selection of cases to be submitted to the Onco-
type Dx test it is advantageous to add Bcl2 to the IHC bio-profile and to select on its own
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dataset PGR and Ki67 cut-off values tailored on Oncotype Dx results rather than to apply
“prognostic” cut-off values. If these results will be confirmed in the new patient dataset being
collected, the addition of Bcl2 to IHC bio-profiles will strongly suggest to submit only those
PGR-positive Ki67 or Bcl2/Ki67 altered cases to Oncotype Dx test, and directly indicate the
need of chemotherapy for those PGR-Negative Ki67 or Bcl2/Ki67 altered cases, showing this
immunohistochemical bio-profiles as a useful pre-selection tool for Oncotype Dx referral at
the time of pathological diagnosis.
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